Note: This story has been sourced from the website, www.thepharmaletter.com and The Australian Business Review.
On Friday, July 7, 2017, Bioverativ filed complaints in the U.S. District Court for the District of Delaware and with the U.S. International Trade Commission alleging that Idelvion, a novel factor IX albumin fusion protein developed by CSL Behring, infringes upon three Bioverativ patents.. Bioverativ says Idelvion is similar to its Alprolix (coagulation Factor IX [recombinant]). CSL has said it could not provide specific details of the infringement claim because it was a litigation matter, but did provide a statement, “CSL is highly confident of its intellectual property position for Idelvion, a product of over a decade of innovative research by CSL Behring and representative of a major advance for patients suffering haemophilia B, and will vigorously defend against the claim.”
HFA is monitoring this story as it develops.
